POZEN Logo
Print Page   Close Window

Press Release

POZEN Announces May 5, 2011 Webcast of First Quarter 2011 Results

CHAPEL HILL, N.C., Apr 21, 2011 (BUSINESS WIRE) --

POZEN Inc. (NASDAQ: POZN),a pharmaceutical company committed to transforming medicine that transforms lives, announced today that it plans to release first quarter 2011 results on May 5, 2011, before the market opens.

The announcement will be followed by a live webcast at 11:00 a.m. (EDT) with a discussion by POZEN management of the earnings and business results. The webcast can be accessed on POZEN's website at www.pozen.com and will be archived and available for replay. The first quarter 2011 earnings release will be accessible in the News section of POZEN's website.

About POZEN

POZEN Inc. is a progressive pharmaceutical company that is transforming how the healthcare industry addresses unmet medical needs. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products in two years - something almost no other small pharmaceutical company has done. Funded by these two milestone/royalty streams, POZEN is now creating a portfolio of cost-effective, evidence based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI toxicity. The lead candidate, PA32540, is being investigated for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced ulcers and has entered Phase 3 clinical trials. POZEN is retaining commercial control of the pipeline assets and will develop a 21st century sales and marketing organization using a new sales force model and digital communications. The Company's common stock is traded on The NASDAQ Stock Market under the symbol "POZN". For more detailed company information, including copies of this and other press releases, please visit: www.pozen.com.

SOURCE: POZEN Inc.

POZEN Inc.
Bill Hodges
Chief Financial Officer
919-913-1030
or
Stephanie Bonestell
Manager, Investor Relations & Public Relations
919-913-1030